AURIGENE DISCOVERY TECHNOLOGIES (M) SDN BHD

Aurigene Discovery Technologies (M) Sdn Bhd based in Technology Park Malaysia is a partnership-focused collaborative Drug Discover organisation with world class infrastructure and personnel in the areas of Medicine Chemistry, Structure Guided Drug Discovery, Molecular and Cell Biology and Preclinical Biology. Aurigene Discovery Technologies (M) Sdn Bhd is a subsidiary of Aurigene Discovery Technologies Limited based in Banglore, which is a 100% subsidiary of Dr. Reddy’s Laboratories Limited, Hyderabad. Dr. Reddy’s is India’s largest pharmaceutical company, with operations in over 40 countries around the world, and listed on the New York and Bombay Stock Exchanges.

Aurigene works exclusively with partners on a project for the different stages of drug discovery called Hit Generation, Lead Generation, Lead Optimization and Pre-Clinical development.

Aurigene is not a CRO; it is a highly science-driven organization, and delivers Intellectual Property to its partners. Unlike typical biotech, where the business model entails a great degree of risk, Aurigene has a unique hybrid model where it is able to run a profitable operation on the strength of its risk-sharing early partnership deals, and therefore has a sustainable business model with the potential to generate long-term value. With over 10 Discovery programs in operation, at this time the company is in a consolidation mode, with a clear edge over potential competitors anywhere in the world.

Aurigene’s unique model makes it a clear leader in the biotech space. The early successes seen in many of the on-going discovery programs gives the company the confidence to be able to build a world class, one-of-its-kind operation taking advantage of the ability to innovate very cost-effectively while remaining a profitable, cost-effective operation.